Advice
Following an abbreviated submission etanercept 50mg subcutaneous injection (Enbrel) is accepted for use within NHS Scotland for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.
Etanercept improves the symptoms of arthritis and psoriasis and may slow the progression of joint damage (at least over a period of one year). The 50mg formulation facilitates once weekly administration of etanercept at no additional cost over the existing 25mg formulation that is administered twice weekly.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- etanercept 50mg subcutaneous injection (Enbrel)
- SMC ID:
- 304/06
- Indication:
- Psoriatic arthritis
- Pharmaceutical company
- Wyeth Pharmaceuticals
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 September 2006